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Abstract
Background: The positive transcription elongation factor b (P-TEFb) is an essential cellular co-
factor for the transcription of the human immunodeficiency virus type 1 (HIV-1). The cyclin T1
(CycT1) subunit of P-TEFb associates with a viral protein, Tat, at the transactivation response
element (TAR). This represents a critical and necessary step for the stimulation of transcriptional
elongation. Therefore, CycT1 may serve as a potential target for the development of anti-HIV
therapies.
Results:  To create effective inhibitors of HIV transcription, mutant CycT1 proteins were
constructed based upon sequence similarities between CycT1 and other cyclin molecules, as well
as the defined crystal structure of CycT1. One of these mutants, termed CycT1-U7, showed a
potent dominant negative effect on Tat-dependent HIV transcription despite a remarkably low
steady-state expression level. Surprisingly, the expression levels of Tat proteins co-expressed with
CycT1-U7 were significantly lower than Tat co-expressed with wild type CycT1. However, the
expression levels of CycT1-U7 and Tat were restored by treatment with proteasome inhibitors.
Concomitantly, the dominant negative effect of CycT1-U7 was abolished by these inhibitors.
Conclusion: These results suggest that CycT1-U7 inhibits HIV transcription by promoting a rapid
degradation of Tat. These mutant CycT1 proteins represent a novel class of specific inhibitors for
HIV transcription that could potentially be used in the design of anti-viral therapy.
Background
The transcription of human immunodeficiency virus type
1 (HIV-1) is a highly regulated process in which several
host cellular co-factors and the viral transactivator protein
Tat are involved [1,2]. Tat stimulates the elongation of
transcription with the aid of the positive transcription
elongation factor b (P-TEFb), a heterodimer comprised of
cyclin T1 (CycT1) and cyclin dependent kinase 9 (Cdk9).
Tat and CycT1 bind to the transactivation response ele-
ment (TAR), an RNA stem loop structure located at the 5'-
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end (+1 to +59) of all viral transcripts [3-5]. This interac-
tion results in the recruitment of Cdk9 and the subse-
quent stimulation of its kinase activity by Tat [6]. Among
three distinct P-TEFb complexes (CycT1/Cdk9, CycT2/
Cdk9, and CycK/Cdk9), only the CycT1/Cdk9 complex
can support Tat transactivation [7-9].
The interaction between Tat, TAR, and CycT1 has been
extensively studied [2-5,8,10]. Tat binds to the bulge
region (+23 to +25) of TAR and the CycT1 subunit of P-
TEFb through its central arginine-rich motif (ARM; a.a.
49–60) and its N-terminal activation domain (a.a. 1–48),
respectively. CycT1, in turn, is thought to bind to the cen-
tral loop (+30 to +35) of TAR through its Tat-TAR recogni-
tion motif (TRM; a.a. 251–271) in the presence of Tat
[1,2]. Human CycT1 is comprised of 726 amino acids and
contains a cyclin box repeat domain (from positions 31 to
250), a coiled-coil sequence (from positions 379 to 530),
and a PEST sequence (from positions 709 to 726). The N-
terminal cyclin boxes are important for binding and acti-
vation of Cdk9. Residues from positions 251 to 272 are
essential for the zinc ion-mediated binding between Tat
and TAR [5]. This region also interacts with the HEXIM1
protein and 7SK small nuclear RNA, which negatively reg-
ulate the kinase activity of P-TEFb [11-15]. The C-terminal
region (a.a. 273–726) of CycT1 is dispensable for Tat
transactivation since the N-terminal cyclin repeats (a.a. 1–
250) and TRM (a.a. 251–272) of CycT1 interact with
Cdk9, Tat and TAR [3-5,9,16,17]. Recently, we have deter-
mined the crystal structure of the N-terminal region (a.a.
1–280) of human CycT1 [18] and its interacting dimeric
Cyclin T-binding domain in HEXIM1 [19].
Since P-TEFb is the essential cellular host co-factor of the
viral Tat protein, this interaction serves as a potential tar-
get for anti-HIV therapeutics. Several approaches have
been taken to block HIV transcription by targeting P-TEFb.
First, mutant Cdk9 proteins defective in kinase activity
have been shown to inhibit HIV transcription in cell cul-
ture systems [20]. A number of small compounds that
inhibit Cdk9 activities or disrupt the Tat/TAR/P-TEFb
interaction have also been tested [20-28]. Another
approach by Napolitano et al. aimed to inactivate Cdk9
by an oligomerization chain reaction [29]. Additionally,
our group has constructed chimeric proteins containing
wild type (wt) CycT1 and mutant Cdk9 which inhibited
HIV replication up to 90% [30]. Moreover, several CycT1-
binding proteins and their truncation mutants have been
used as inhibitors of Tat transactivation [31-33]. Finally,
Bai et al. demonstrated that intrabodies against CycT1
inhibited Tat stimulated transactivation [34]. It is impor-
tant to note, however, that because P-TEFb is involved in
the transcription of many cellular genes [35], it is critical
to exclusively block HIV-specific pathways in order to
develop safe and effective anti-HIV therapies.
In this study, we sought to construct dominant negative
CycT1 mutant proteins capable of blocking HIV transcrip-
tion. A sequence alignment between the cyclin proteins
CycT1, T2 and K revealed ten very well-conserved regions
that are essential for the formation of the alpha-helical
cyclin box repeat domain. We introduced random muta-
tions in the nine most conserved amino acid clusters in
these regions and tested the resulting mutant CycT1 pro-
teins for their ability to block HIV transcription. One of
the mutant proteins, called CycT1-U7, showed a potent,
yet specific, dominant negative effect on HIV transcrip-
tion, although the steady-state expression level of CycT1-
U7 was remarkably low. Western blot analysis indicated
that the expression level of the Tat proteins co-expressed
with CycT1-U7 was also significantly lower than those co-
expressed with wt CycT1. Proteasome inhibitors restored
the expression of CycT1-U7 and Tat proteins. As a conse-
quence, these inhibitors diminished the dominant nega-
tive effect elicited by over-expression of CycT1-U7. Our
results suggest that CycT1-U7 inhibits HIV transcription
by promoting a rapid degradation of Tat proteins. These
mutant CycT1 proteins represent a novel class of specific
inhibitors for HIV transcription, which might be further
utilized in development of safe and effective anti-HIV
therapies.
Results
Construction and screening of CycT1 mutants
CycT1 is a member of the C-type cyclin family [36]. Its N-
terminal 250 amino acids form two cyclin repeat boxes
that are essential for the interaction with, and the activa-
tion of, Cdk9. Recently, we have determined the three
dimensional crystal structure of CycT1 [18]. The cyclin
boxes consist of two repeats, each containing five α-heli-
ces (Figure. 1A and 1B). Sequence alignment of three P-
TEFb-forming cyclins T1, T2, and K from different species
revealed that the secondary structure elements are well
conserved among these cyclins, indicating that they play
important roles in P-TEFb functions (Figure. 1B). Based
on this secondary structure alignment, we selected the
nine most conserved amino acid clusters in the cyclin box
domain of CycT1 and introduced random mutations into
a C-terminal truncation mutant of CycT1 (CycT1(1–
280)). This truncation is sufficient to support Tat transac-
tivation as described before [4,5,9] (Figure. 1C and Table
1).
Mutations were introduced by oligonucleotides contain-
ing degenerate nucleotides corresponding to each con-
served region. In total, 115 CycT1 mutants were
constructed and tested for their activities on Tat transacti-
vation by co-transfecting murine NIH 3T3 cells with an
HIV LTR-Luciferase (Luc) reporter gene and Tat (Table 1).
Since murine endogenous CycT1 (mCycT1) cannot sup-
port Tat transactivation, Tat activated the LTR-driven LucRetrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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expression only by approximately 10-fold (Figure. 2A,
lane 2). Over-expression of the wt human CycT1 further
activated the gene expression up to 70-fold (Figure. 2A,
lanes 3 and 4). The luciferase activities obtained by over-
expressing any of the pool of mutant CycT1 proteins
ranged from five to 70-fold. Fifteen mutants showed an
equal or a higher activity than the wt, 45 mutants showed
modest (50–100% of wt) activity and 55 had less than
50% of the activity of wt CycT1 in these cells (summarized
in Table 1). These 55 mutants were further sequenced and
tested for their dominant negative effect on HIV transcrip-
tion by co-transfecting HeLa cells stably expressing the
HIV-Luc reporter gene (HeLa/HR-Luc cells) with Tat (Fig-
ure. 2B and data not shown).
An N-Terminal CycT1 mutant exhibited the strongest 
dominant negative effect on Tat transactivation by 
promoting the degradation of Tat proteins
Amongst the 55 clones tested for their ability to block Tat
transactivation in HeLa cells, one mutant containing four
amino acid substitutions and one deletion in the second
helix H2 of the N-terminal cyclin box repeat (residues
HRFYM at a.a. position 67–71 to IIWE; Figure. 1B),
termed CycT1-U7, showed the strongest dominant nega-
tive effect (>90% inhibition) on HIV transcription in
HeLa/HR-Luc cells (Figure. 2B, lanes 3 to 5). At least four
other mutant CycT1 constructed by the same oligonucle-
otides (Mut 2, Additional file 1) showed potent dominant
negative effects on HIV transcription (60–90%, data not
Construction of mutant CycT1 proteins Figure 1
Construction of mutant CycT1 proteins.A. Structure of the cyclin box repeat domain (1–281) of CycT1. Two repeats of 
five α-helices each form the conserved cyclin box (blue). Flanking N- and C-terminal helices, which are important for the spe-
cificity of cyclins, are depicted in yellow and red, respectively. B. Schematic representation of C-terminally truncated wt CycT1 
and the dominant negative CycT1-U7 mutant used in this study. Secondary structure of conserved α-helices (dotted regions in 
cyclin box 1 and hatched regions in cyclin box 2) together with two helices at N- and C-terminal (gray) locate in the N-termi-
nal cyclin boxes in CycT1. Random mutations were introduced into the nine most conserved regions (shown by thin lines) in 
the cyclin box domain of a C-terminal truncation mutant of CycT1 (CycT1(1–280)). "-" in the CycT1-U7 sequence represents 
a deletion site. The truncated wt and mutant CycT1 employed in this study are also shown. C. A schematic representation of 
the full-length Cyclin T1. Amino acid motifs such as cyclin boxes, Tat-TAR recognition motif (TRM), coiled-coiled region, and 
PEST sequence are depicted.Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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shown). Over-expression of CycT1-U7 affected neither the
basal HIV transcription nor CMV-Luc reporter gene
expression (Figure. 2C). Next, HeLa/HR-Luc cells stably
expressing CycT1-U7 were created by infecting with a sec-
ond lentiviral vector. Tat transactivation in these cells was
scored by transfecting an increasing amount of Tat and
measuring LTR-driven luciferase activity. In cells express-
ing CycT1-U7, Tat exhibited a significantly lower activity
compared to the cells stably carrying the empty pHR len-
tiviral vector (Figure. 2D). Western blot analysis revealed
that the steady-state expression level of CycT1-U7 is much
lower than wt CycT1 (1–280) although the same amount
of plasmid was transfected (Figure. 3A, lanes 2 and 3 in
the top panel). Interestingly, the expression level of Tat
was also much lower in CycT1-U7-expressing cells than in
wt CycT1 (1–280) expressing cells, (Figure. 3A, lane 2 and
3). In contrast, the expression levels of the endogenous
CycT1 and Cdk9 in the presence of CycT1-U7 remained
unchanged (Figure. 3A). These results suggested that Tat
transactivation in CycT1-U7 expressing cells is kept at a
low level because the steady state Tat expression is dimin-
ished in these cells. Since CycT1-U7 retains the wild type
sequence of Tat-TAR recognition motif (Figure. 1C), we
hypothesized that CycT1-U7 forms a complex with Tat,
and this complex is rapidly degraded in cells.
Expression of CycT1-U7 and Tat can be rescued by 
proteasome inhibitors
To further prove our hypothesis that CycT1-U7, together
with Tat, is rapidly transferred to proteasomal degradation
pathways, cells expressing Tat and either wt CycT1 (1–
280) or mutant CycT1-U7 were incubated with the protea-
some inhibitors, MG-132 (50 μM) or Epoxomicin (50
μM) for 1, 3, and 5 hours prior to cell lysis. MG-132
showed a strong cytopathic effect when incubated for 5
hours (data not shown). The expression of both CycT1-U7
and Tat was partially restored in the presence of MG-132
(Figure. 3B, lanes 2 and 3 compared with lane 1), and
much more efficiently restored in the presence of Epox-
omicin (Figure. 3B, lanes 5 to 7 compared with lane 4). In
contrast, the expression of wt CycT1 (1–280) and Tat
remained virtually unchanged in the presence of these
inhibitors (lanes 9 and 10 compared with lane 8).
The restoration of the CycT1-U7 and Tat expression by
Epoxomicin was also observed at the cellular level by an
indirect immuno-fluorescence (IF) assay (Figure. 4A). HA-
tagged wt and mutant CycT1 and myc-tagged Tat proteins
were co-expressed in HeLa/HR-Luc cells. Twenty-four
hours after transfection, cells were untreated or treated
with 25 μM Epoxomicin for 3 hours. HA-CycT1 proteins
were probed with mouse anti-HA and Cy2-conjugated
anti-mouse IgG, and myc-Tat proteins were probed with
Texas Red-labelled anti-myc antibody. As shown in Fig-
ure. 4A, the expression of CycT1-U7 and Tat was kept at
low levels without Epoxomicin treatment. The protein
levels were elevated when the cells were treated with Epox-
omicin. The wt CycT1 and Tat proteins co-expressed with
wt CycT1 were detected in the presence or absence of
Epoxomicin. Finally, the inhibitory effect by CycT-U7 was
diminished in transient (Figure. 4B) and stable (Figure.
4C) expression systems when the cells were incubated
with 25 μM Epoxomicin for 6 to 18 hours. Since it has
been demonstrated that CycT1 is ubiquitinated in cells
[37], we sought to examine whether CycT1-U7 is ubiqui-
tinated by co-immunoprecipitation analysis (Figure. 5A).
Ubiquitinated CycT1-U7 proteins were detected in HeLa/
CycT1-U7 cells treated with 50 μM Epoxomicin for 60
min (Figure. 5A, lane 2). Also, in this condition, the inter-
action between CycT1-U7 and Tat was detected by co-
immunoprecipitation (Figure. 5B, lane 4). These results
suggest that CycT1-U7 inhibits Tat-transactivation by rap-
idly recruiting Tat proteins into an ubiquitin-dependent
proteasomal degradation pathway.
Table 1: Overview of CycT1 mutants used in this study.
Regions Helix# Amino acid positions # of clones Activity in murine cells (*1)
>100% 50–100% <50%
Region 1 2 58–65 29 4 14 11
Region 2 2 67–71 26 3 10 13
Region 3 3 88–91 16 2 5 9
Region 4 3 93–96 16 3 11 2
Region 5 4 104–108 5 0 0 5
Region 6 5 132–137 3 0 1 2
Region 7 5 139–143 9 0 0 9
Region 8 5 145–148 2 0 0 2
Region 9 1' 149–152 9 3 4 2
total 115 15 45 55
*1: Tat transactivation obtained with wt human CycT1 is set as 100%Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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Discussion
Although P-TEFb is a potential target for the development
of novel anti-HIV therapies, it had been extremely difficult
to construct dominant negative CycT1 mutants that block
HIV transcription [30]. This is presumably due to the high
stability and the complex regulatory mechanism of the
endogenous P-TEFb complex. In the present study, we
constructed and evaluated a novel class of CycT1 mutant
proteins (CycT1-U7) that explicitly block HIV transcrip-
tion by promoting a rapid and specific degradation of Tat
proteins co-expressing CycT1-U7. Resulting from a func-
tional screen of 115 randomized mutant proteins,
sequence analysis of CycT1-U7 showed five mutations
including one amino acid deletion in the second helix of
N-terminal mutant CycT1 proteins (CycT1-U7) exhibit a strong dominant negative effect on HIV transactivation Figure 2
N-terminal mutant CycT1 proteins (CycT1-U7) exhibit a strong dominant negative effect on HIV transactiva-
tion.A. CycT1-U7 cannot support Tat transactivation in murine cells. NIH 3T3 cells were transfected with HIV-Luc reporter 
gene in the presence (lane 2–6) or absence (lane 1) of Tat (0.1 μg) with or without increasing amounts (0.2 and 0.5 μg) of wt 
human CycT 1–280 (lanes 3 and 4) or CycT1-U7 (lanes 5 and 6). Twenty-four hours after transfection, luciferase activities 
were measured as described before. B. CycT1-U7 shows strong dominant negative effects on Tat-transactivation. Increasing 
amounts of CycT1-U7 (0.2, 0.4 and 0.6 μg) were transfected in HeLa/pHR-Luc cells in the presence of Tat (0.02 μg). Luciferase 
activities were measured as described above. C. CycT1-U7 was unable to inhibit basal HIV transcription and CMV-driven tran-
scription. The plasmid (0.6 μg) encoding CycT1-U7 (gray bars) or an empty vector (black bars) was co-transfected in HeLa 
cells with HIV-LTR-Luciferase or CMV-Luciferase reporter plasmid (0.05 μg) in the absence of Tat. Luciferase activity was 
measured as described above. D. Tat has lower activity on HIV-LTR in cells stably expressing CycT1-U7. Increasing amounts of 
Tat were transfected in Hela/pHR-Luc cells stably carrying a lentiviral vector encoding no protein (empty vector; gray dia-
monds) or CycT1-U7 proteins (black triangle). Luciferase activities were measured as described in the Materials and Methods 
section. Error bars represent the standard deviation of triplicate measurements. Data are representative of four independent 
assays.Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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the cyclin box repeat fold (Figure. 1B). We have previously
demonstrated that a CycT1 variant lacking this region
(CycT1 (119–280)) is also unstable in cells [38]. This par-
ticular mutant exhibited a potent dominant negative
effect on HIV transcription, potentially by a similar mech-
anism (data not shown). Therefore, H2 of CycT1 appears
very important for maintaining the structural stability of
CycT1 and the interface in between the two repeats. In
addition, a residue directly preceding the first helix of the
cyclin box repeat that varies between human and equine
CycT1 has been previously identified as responsible for
differences in the recognition of Tat/TAR complexes from
HIV and EIAV [39]. Together, these data point towards the
importance of the integrity of the first cyclin box repeat for
the interaction with Tat. This region also appears to be
essential for the interaction with Cdk9 [18,30]. Interest-
ingly, CycT1-U7 does not promote degradation of endog-
enous Cdk9. On the other hand, this mutant does bear the
wild type sequence of Tat/TAR recognition motif (a.a.
251–272). Indeed, the complex between CycT1-U7 and
CycT1-U7 promotes the degradation of Tat Figure 3
CycT1-U7 promotes the degradation of Tat. A. Western blotting depicts the steady-state expression of Tat proteins 
co-expressed with wt or mutant CycT1. HA-epitope tagged Tat (lanes 1–3) and HA-tagged CycT1 1–280 (wt: lane 2) or HA-
CycT1-U7 (lane 3) were co-expressed in 293T cells. Twenty-four hours after transfection, cells were lysed with RIPA buffer 
(25 mM Hepes-KOH, 150 mM KCl, 1 mM EDTA, 1% Triton X100, 0.1% NP-40, pH 7.4), and soluble proteins were separated 
by 12% SDS-PAGE. The ectopically expressed CycT1 and Tat proteins were detected by anti-HA antibody. The endogenous 
proteins (CycT1, Cdk9 and Tubulin) were also detected by Western blotting. B. The expression of CycT1-U7 and Tat was 
restored by proteasome inhibitors. 293T cells were transfected with HA-tagged wt CycT1 (1–280) (lanes 8 to 10) or HA-
CycT1-U7 (lanes 1 to 7) and HA-Tat as described above. Twenty-four hours after transfection, cells were treated with DMSO 
(lanes 1, 4 and 8), MG-132 (50 μM: lanes 2, 3 and 9) or Epoxomicin (50 μM: lanes 4 to 7 and 10) for 1 (lanes 2 and 5), 3 (lanes 
3, 6, 9 and 10) and 5 hours (lane 7). Cells were then lysed in RIPA buffer and subjected to SDS-PAGE. The ectopically 
expressed CycT1 and Tat proteins were detected by anti-HA antibodies.Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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Epoxomicin restores CycT1-U7 and Tat expression Figure 4
Epoxomicin restores CycT1-U7 and Tat expression.A. HA-tagged wt and mutant CycT1 and myc-tagged Tat proteins 
were co-expressed in HeLa/HR-Luc cells. Twenty-four hours after transfection, cells were untreated or treated with 25 μM 
Epoxomicin for 3 hours. HA-CycT1 proteins were visualized with mouse anti-HA antibody and Cy2-conjugated donkey anti-
mouse IgG. Myc-Tat proteins were seen with Texas Red-conjugated anti-myc antibody. Nuclei were stained with Hoechst. B. 
The inhibitory effect by CycT1-U7 was diminished by Epoxomicin. HeLa/HR-Luc cells were transfected with CycT1-U7 expres-
sion plasmids (0.5 μg) or empty plasmids (0.5 μg) in the presence of Tat. Cells were treated with DMSO (-) or 25 μM Epox-
omicin for 6 hours and 18 hours as indicated, and the Luc activities were measured. The results were presented as relative 
luciferase values obtained with CycT1-U7 divided by the values with the empty vector at each time point. C. Increasing 
amounts of Tat were transfected in Hela/pHR-Luc cells stably expressing CycT1-U7 proteins. 24 hours after transfection, cells 
were untreated (open circles) or incubated (closed circles) with Epoxomicin (25 μM) for 6 hours prior to luciferase assay. Data 
are presented as fold activation relative to the value obtained with untreated cells. Error bars represent the standard deviation 
of triplicate measurements. Data are representative of three independent assays.Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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Tat was detected when the cells were treated with proteas-
ome inhibitors (Figure. 5). The mutant CycT1-U7 proteins
can form a complex with Tat and this complex would be
immediately degraded because of the instability of CycT1-
U7. Therefore, we conclude that CycT1-U7 exhibits a
strong dominant negative effect on Tat transactivation by
specifically degrading the co-expressed Tat protein, with-
out disturbing the endogenous P-TEFb complex (Figure.
6).
It has been demonstrated that CycT1 interacts with other
cellular transcription factors through its N-terminal cyclin
box regions [40,41]. It is of importance to examine
whether CycT-U7 can also inhibit cellular transcription
mediated by these factors via a similar pathway. Addition-
ally, the TRM region of CycT1 also interacts with HEXIM1,
the endogenous inhibitory protein of P-TEFb which inter-
acts with this region [11], and it is possible that CycT1-U7
affects P-TEFb activity by reducing HEXIM1 levels. More
detailed studies are required to assess the effect of CycT1-
U7 on cellular transcription.
Our results indicate that CycT1-U7/Tat is recruited to the
ubiquitin-dependent degradation pathway. CycT1 seems
to be ubiquitinated not only on its C-terminal PEST
region (a.a. 706–726) but also at other regions [37]. It is
to be noted that wt CycT1 (1–280) is resistant to degrada-
tion (Figure. 3). Although we have not identified the
CycT1-U7 is ubiquitinated Figure 5
CycT1-U7 is ubiquitinated.A. HeLa cells stably expressing myc-CycT1-U7 proteins (HeLa/myc-CycT1-U7) were treated 
(lanes 1 and 2) or untreated (lane 3) with Epoxomicin (50 μM) for 30 min prior to cell lysis. The Myc-CycT1-U7 proteins were 
immunoprecipitated with anti-Myc antibody followed by Western blot analysis with anti-Ub antibody to detect ubiquitinated 
Myc-CycT1-U7 proteins (upper panel). Normal mouse IgG (mIgG) was used as a negative control for immunoprecipitation 
(lane 1). The expression of the Myc-CycT1-U7 proteins in 10% of the input samples was also detected by Western blot analysis 
using anti-Myc antibody (lower panel). B. CycT1-U7 binds Tat. HeLa/Myc-CycT1-U7 cells were transfected with HA-Tat. The 
cells were treated (lanes 1, 3 and 4) or untreated (lanes 2, 4 and 5) with Epoxomicin (50 μM) for 30 min prior to cell lysis. The 
Myc-CycT1-U7 proteins were immunoprecipitated with anti-Myc antibody (lanes 4 and 6) followed by Western blot analysis 
with anti-HA antibody to detect Tat proteins. Normal rabbit IgG (rIgG) was used as a negative control (lanes 3 and 5). Tat pro-
teins in the input samples (10%) were also shown (lanes 1 and 2).Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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potential ubiquitination site(s) of CycT1-U7 in this study,
it is possible that the cyclin box structure stabilizes the
protein by preventing ubiquitination. Conformational
changes induced by post-translational modifications such
as phosphorylation may expose any additional ubiquiti-
nation sites in this region, which would represent a novel
pathway to regulate P-TEFb function.
Constructing CycT1 mutants based on C-terminal trun-
cated forms of wt CycT1 (CycT1(1–280)) is particularly
beneficial in terms of HIV transcription. CycT1 (1–280)
has been demonstrated to be sufficient for supporting Tat-
transactivation [4,5,9]. In addition, Tat competes with
HEXIM1 to increase active P-TEFb complexes [14,15,19].
CycT1 (1–280) can therefore bypass the 7SK/HEXIM-
mediated complex regulatory pathway and be exclusively
directed towards Tat-dependent transactivation (Jad-
lowsky et al., unpublished data), making CycT1 (1–280)
proteins highly specific for Tat.
Since the mechanism by which CycT1-U7 inhibits HIV
transcription seems not to be through blocking the nor-
mal function of P-TEFb, but rather through a "gain-of-
function" pathway, it represents a novel class of inhibitory
molecules. Moreover, since the steady-state expression of
CycT-U7 is very low, it may be an excellent candidate for
gene therapy because the mutant proteins would not per-
sist for a prolonged period of time, thereby avoiding
induction of unwanted immune responses. Additionally,
these proteins would work only when Tat is actively
expressed in cells.
HIV utilizes the cellular transcriptional machinery for its
own replication. Therefore, it is important to inhibit this
Proposed model for the mechanism of dominant negative effect elicited by CycT1-U7 Figure 6
Proposed model for the mechanism of dominant negative effect elicited by CycT1-U7. Wild type CycT1 forms a 
complex with Cdk9 as an active P-TEFb, and interacts with Tat and TAR RNA. Alternatively, CycT1-U7 associates with Tat but 
the CycT-U7/Tat complex is immediately degraded via an ubiquitin-dependent proteasomal pathway. This degradation can be 
prevented using proteasome inhibitors.Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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step without disturbing cellular functions. Since CycT1
interacts with Tat and TAR, it can be an excellent target to
develop safe and effective anti-HIV therapies. Here we
present an example of a dominant negative CycT1 mole-
cule which specifically blocks HIV transcription. Studying
the precise mechanism by which this mutant CycT1 pro-
tein inhibits HIV transcription could unveil novel regula-
tory pathways of the HIV life cycle and therefore provide
reliable clues for designing anti-HIV agents.
Conclusion
In this study, we constructed and evaluated dominant
negative CycT1 mutant proteins that specifically block
HIV transcription by promoting a rapid degradation of Tat
proteins. These mutant CycT1 proteins represent a novel
class of specific inhibitors for HIV transcription, which
can be further utilized to develop a safe and effective anti-
HIV therapy.
Methods
Materials
HeLa, 293T or NIH 3T3 cells were maintained in Dul-
becco's Modified Eagle's Medium (DMEM) including
10% fetal bovine serum at 37°C with 5% CO2. HeLa cells
stably carrying an HIV-LTR-driven luciferase reporter gene
(HeLa-HR-Luc cells) were established using pHR lentiviral
vector expressing the luciferase gene under the control of
the HIV-LTR, as described previously [42,43]. Anti-myc,
anti-HA, anti-CycT1, anti-Cdk9, and anti-Ub antibodies
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-actin antibody was purchased from Cell
Signaling Technology (Danvers, MA). Anti-Tubulin was
purchased from Sigma Aldrich (St. Louis, MO). Proteas-
ome inhibitors, MG-132 and Epoxomicin were purchased
from EMD Bioscience (San Diego, CA) and Alexis (San
Diego, CA), respectively.
Construction of CycT1 mutants
A structure-based sequence alignment resulting from the
crystal structure of the cyclin box repeat of human CycT1
[18] revealed highly conserved α-helical structures in the
P-TEFb-forming cyclins T1, T2 and K (Figure. 1B). Based
on this alignment, we selected the nine most conserved
regions in the cyclin box repeat domain of CycT1 and
introduced random mutations into a C-terminal trunca-
tion mutant of CycT1 (1–280) by using oligonucleotides
that contain degenerated nucleotides at positions corre-
sponding to each conserved helix and the Transformer
Site Directed Mutagenesis Kit (Clontech) (Figure. 1 and
Table 1). The resulting 115 CycT1 mutants were tested for
their ability to support Tat transactivation in murine cells
as described previously [4]. The CycT1 mutants that failed
to activate HIV-transcription in murine cells were
sequenced and further tested for their ability to block Tat
transactivation in HeLa cells as described previously [30].
The mutant CycT1 (termed CycT1-U7) that exhibited the
strongest inhibitory effect on Tat-dependent HIV tran-
scription was used in this study. Sequences of the muta-
genic oligonucleotides are shown in Additional file 1.
Generation of stable cell lines
CycT-U7 was subcloned downstream of a CMV promoter
in a modified pHR'-SIN lentiviral vector [44,45]. The VSV-
G pseudotyped lentiviruses were produced by co-transfec-
tion with packaging plasmids (pMDG and p8.9I, [46]),
and used to infect Hela cells and HeLa-HR Luc cells.
Transfection and reporter assays
HeLa or NIH 3T3 cells were transfected with 0.5 μg of pEF-
CycT1 (wt or mutant constructs) and an HIV-Luciferase
reporter construct, in the presence or absence of pTat
(0.01  μg) using Lipofectamine 2000 according to the
manufacturer's instructions (Invitrogen). Twenty-four
hours after transfection, cells were harvested and lysed.
The protein concentrations of the cell lysates were deter-
mined by Protein Assay kit (BioRad). Luciferase activities
in the cell lysates were measured as described previously
[43].
Ubiquitination assays
HeLa cells stably expressing myc-epitope tagged mutant
CycT1 proteins were expressed and, when indicated,
treated with 50 μM Epoxomicin for 1 hour. Cells were
lysed in radio-immunoprecipitation assay (RIPA) buffer
(50 mM Tris-HCl, 0.15 M NaCl, 1 mM EDTA, 1% Sodium
deoxycholate, 1% NP-40, 0.1% SDS, 1 mM DTT [pH 7.4])
in the presence of protease inhibitors. After preclearing
with protein-G sepharose coupled with normal mouse
IgG, cell lysates were incubated with 0.5 μg of monoclonal
antibody against c-Myc (F-7; Santa Cruz Biotechnology)
overnight at 4°C. After the cell lysates were allowed to
bind to the antibody, reaction mixtures were incubated
with protein-G sepharose beads (Roche) for 1 hour at
4°C. The beads were washed extensively with RIPA buffer
and the proteins remaining on the beads were eluted by
incubation with SDS loading buffer (50 mM Tris-HCl, 2%
SDS, 10% glycerol, 2 mM EDTA, 0.1 M DTT and 0.01%
bromophenol blue, pH 6.8) and subjected to SDS-PAGE,
followed by Western blotting with anti-Ub antibody
(Santa Cruz Biotechnology).
Proteasome inhibitor treatment
293T cells (2 × 105) were transfected with 1 μg of plasmids
encoding HA-tagged wt CycT1 (1–280) or CycT1-U7 in
the presence or absence of the plasmid encoding HA-
tagged HIV-1 Tat (0.2 μg) using calcium phosphate.
Twenty-four hours post-transfection, cells were treated
with MG-132 (50 μM), Epoxomicin (50 μM) or DMSO
(solvent control) at 37°C for 1, 3 and 5 hours. Cells were
then harvested and lysed in RIPA buffer. The protein con-Retrovirology 2008, 5:63 http://www.retrovirology.com/content/5/1/63
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centrations in the cell lysates were determined by Protein
Assay Kits (BioRad, Palo Alto, CA). The same amounts of
cellular proteins (20 μg) were separated by SDS-PAGE fol-
lowed by Western blot analysis to detect the HA-epitope
tagged CycT1 proteins and myc-epitope tagged Tat pro-
teins.
Immunofluorescence (IF) assay
HA-tagged wt and mutant CycT1 and myc-tagged Tat pro-
teins were co-expressed in HeLa/HR-Luc cells using Lipo-
fectin (Invitrogen). Twenty-four hours after transfection,
cells were untreated or treated with 25 μM Epoxomicin for
3 hours. Cells were fixed with 4% formaldehyde and
blocked with phosphate-buffered saline (PBS) containing
0.1% Triton X-100, 1% sodium azide and 10% normal
donkey serum. After washing with PBS, HA-CycT1 and
were probed with mouse anti-HA monoclonal antibody
(Santa Cruz) and Cy2-conjugated donkey anti-mouse IgG
(Jackson ImmunoResearch). Myc-Tat proteins were
probed with anti-Myc monoclonal antibody (Santa Cruz)
pre-labeled with Zennon ® Texas Red ® anti-Mouse IgG1
(Invitrogen). Nuclei were stained with Hoechst (Sigma).
Fixed cell images were captured on a Deltavision DV-RT
(Applied Precision, Inc. Issaquah, WA.) microscopy sys-
tem using the Deltavision Softworx program.
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